Barinthus Biotherapeutics (NASDAQ:BRNS) Upgraded by Zacks Research to “Hold” Rating

Barinthus Biotherapeutics (NASDAQ:BRNS) was upgraded by analysts at Zacks Research to a “hold” rating in a report released on Wednesday,Zacks.com reports.

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $4.00.

Barinthus Biotherapeutics Trading Up 3.5%

Shares of BRNS stock opened at $0.73 on Wednesday. The company has a market cap of $29.87 million, a P/E ratio of -0.71 and a beta of -0.39. The firm has a fifty day moving average price of $0.62 and a 200 day moving average price of $0.63. Barinthus Biotherapeutics has a 12 month low of $0.51 and a 12 month high of $1.83.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. On average, equities analysts forecast that Barinthus Biotherapeutics will post -0.93 EPS for the current year.

Institutional Trading of Barinthus Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rangeley Capital LLC grew its stake in Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after buying an additional 75,024 shares during the last quarter. Renaissance Technologies LLC increased its position in Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after buying an additional 76,800 shares during the period. Finally, Baird Financial Group Inc. grew its position in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after acquiring an additional 100,000 shares during the last quarter. 25.20% of the stock is owned by hedge funds and other institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.